Validation Data Gallery
|Positive IP detected in||HeLa cells|
|Positive IHC detected in||human placenta tissue, human breast cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HepG2 cells|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:250-1:1000|
|Immunofluorescence (IF)||IF : 1:10-1:100|
|Sample-dependent, check data in validation data gallery|
14139-1-AP targets ADAM12 in WB, IP, IHC, IF, FC, ELISA applications and shows reactivity with human, mouse samples.
|Tested Reactivity||human, mouse|
|Cited Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||ADAM12 fusion protein Ag5206|
|Full Name||ADAM metallopeptidase domain 12|
|Calculated molecular weight||100 kDa|
|Observed molecular weight||90-100 kDa, 70-80 kDa|
|GenBank accession number||BC060804|
|Gene ID (NCBI)||8038|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
ADAM12, also named as MLTN and Meltrin-alpha, is involved in skeletal muscle regeneration, specifically at the onset of cell fusion. It is also involved in macrophage-derived giant cells (MGC) and osteoclast formation from mononuclear precursors. ADAM12 is expressed in human malignant tumors(PMID:17355265). ADAM12's ability to degrade extracellular matrix components likely allows it to detach cancer cells from the basement membrane and assist them on their route to metastasis. But the protein's role not just as a biomarker of breast cancer but as a gateway to cancer cell migration is only now being understood. ADAM12 has 2 isoforms with the calculated molecular mass of 100 and 80 kDa, and this antibody can recognize all isoforms of ADAM12. ADAM12 has 4 forms: 120kDa full-length form, 90kd mature (processed form that lack the prodomain), 50-68kDa degradation product and 27kDa prodomain.
|Product Specific Protocols|
|WB protocol for ADAM12 antibody 14139-1-AP||Download protocol|
|IHC protocol for ADAM12 antibody 14139-1-AP||Download protocol|
|IF protocol for ADAM12 antibody 14139-1-AP||Download protocol|
|IP protocol for ADAM12 antibody 14139-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Int J Mol Med
ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways.
Nucleic Acids Res
Genetic screens reveal mechanisms for the transcriptional regulation of tissue-specific genes in normal cells and tumors.
Calcif Tissue Int
Involvement of ADAM12 in Chondrocyte Differentiation by Regulation of TGF-β1-Induced IGF-1 and RUNX-2 Expressions.
J Proteome Res
SILAC Quantitative Proteomics and Biochemical Analyses Reveal a Novel Molecular Mechanism by which ADAM12S Promotes the Proliferation, Migration, and Invasion of Small Cell Lung Cancer Cells through Upregulating Hexokinase 1.
Pathol Res Pract
Methylation status of ADAM12 promoter are associated with its expression levels in colorectal cancer.
FEBS Open Bio
Selective estrogen receptor modulators decrease invasiveness in pituitary adenoma cell lines AtT-20 and TtT/GF by affecting expression of MMP-14 and ADAM12.